Also known as: VITILIGO
DrugDrug NameDrug Description
DB00337PimecrolimusPimecrolimus is an immunomodulating agent used in the treatment of atopic dermatitis (eczema). It is currently available as a topical cream, once marketed by Novartis, (however Galderma will be promoting the molecule in Canada in early 2007) under the trade name Elidel. [Wikipedia]
DB00864TacrolimusTacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condition vitiligo. It was discovered in 1984 from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis. Tacrolimus is chemically known as a macrolide. It reduces peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP-12 (FK506 binding protein) creating a new complex. This FKBP12-FK506 complex interacts with and inhibits calcineurin thus inhibiting both T-lymphocyte signal transduction and IL-2 transcription.
DrugDrug NamePhaseStatusCount
DB01281Abatacept1Recruiting1
DB04931Afamelanotide1Completed1
DB04931Afamelanotide2Completed1
DB05676Apremilast2Recruiting2
DB01076Atorvastatin2Active Not Recruiting1
DB00005Etanercept2Completed1
DB08877Ruxolitinib2Recruiting1
DB00641Simvastatin2Completed1
DB00620Triamcinolone2Recruiting1
DB00864Tacrolimus2 / 3Terminated1
DB00620Triamcinolone2 / 3Recruiting1
DB00864Tacrolimus3Recruiting1
DB00316Acetaminophen4Unknown Status1
DB00905Bimatoprost4Withdrawn1
DB01114Chlorphenamine4Unknown Status1
DB00514Dextromethorphan4Unknown Status1
DB00764Mometasone4Unknown Status1
DB00388Phenylephrine4Unknown Status1
DB00337Pimecrolimus4Unknown Status1
DB00864Tacrolimus4Unknown Status2
DB01632Alpha-Phosphoribosylpyrophosphoric AcidNot AvailableNot Yet Recruiting1
DB00588Fluticasone propionateNot AvailableWithdrawn1